LAUSR.org creates dashboard-style pages of related content for over 1.5 million academic articles. Sign Up to like articles & get recommendations!

Paeonol inhibits chronic constriction injury‐induced astrocytic activation and neuroinflammation in rats via the HDAC/miR‐15a pathway

Photo by art_almighty from unsplash

Neuropathic pain affects millions of people in the worldwide, but the major therapeutics perform limited effectiveness. Paeonol (PAE) is widely distributed in Paeonis albiflora, and has manifested anti‐inflammatory and antioxidative… Click to show full abstract

Neuropathic pain affects millions of people in the worldwide, but the major therapeutics perform limited effectiveness. Paeonol (PAE) is widely distributed in Paeonis albiflora, and has manifested anti‐inflammatory and antioxidative effects in multiple diseases. The present study aims to elucidate the effect of Paeonol (PAE) on neuropathic pain (NP) and the potential targets. Chronic constriction injury model was established to mimic NP in vivo in rats. The expression of GFAP, HDAC2, AHDAC3, Ac‐H3K9, Histone‐H3, Ac‐H4K12, Histone‐H4, TNF‐α, IL‐1β, and IL‐6 was assessed by real‐time polymerase chain reaction, western blot, and/or enzyme‐linked immunosorbent assay kits. Ultimately, results indicated that intervention of PAE significantly blocked neuroinflammation and astrocytic activation via blocking HDAC/miR‐15a signaling in CCI rats. These data revealed PAE is a novel therapeutic target for the treatment of neuropathic pain.

Keywords: hdac mir; paeonol; astrocytic activation; constriction injury; mir 15a; chronic constriction

Journal Title: Drug Development Research
Year Published: 2022

Link to full text (if available)


Share on Social Media:                               Sign Up to like & get
recommendations!

Related content

More Information              News              Social Media              Video              Recommended



                Click one of the above tabs to view related content.